Latest Administration News

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Radiopharm Theranostics has secured a clinical supply agreement with Siemens Healthineers to manufacture and distribute RAD101, advancing its Phase 3 trial in the U.S. Interim Phase 2b data showed 90% concordance with MRI in detecting brain metastases.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.

Tesoro Gold has issued a replacement Appendix 5B for the December 2025 quarter to correct an administrative error and reclassify certain deposits, ensuring consistency with its audited FY2025 financial statements.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

CVC Limited has addressed ASX concerns over a delayed Appendix 3Y filing related to director John Leaver’s interest change, attributing the delay to administrative oversight while affirming existing compliance policies.

Dome Gold Mines Ltd launches a $3 million convertible note offering to fund key developments in Fiji, including the Sigatoka Feasibility Study and expanded exploration for copper, gold, and silver.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.

Haranga Resources is set to launch a 4,000-metre reverse circulation drilling program at its Ibel South Gold Project in Senegal, aiming to extend high-grade gold mineralisation at depth and explore fresh anomalies identified by termite mound sampling.

Andromeda Metals faces uncertainty in securing cornerstone funding for its Great White Project due to Middle East geopolitical tensions, while pushing forward with its High Purity Alumina pilot plant commissioning.

Optiscan Imaging Ltd has taken a significant step towards commercialising its InSpecta® veterinary imaging device in the US by submitting a regulatory dossier to the FDA. This milestone not only initiates formal review but also sets the stage for broader clinical adoption and future device approvals.